Amgen's Q4 earnings beat expectations, showcasing robust performance for the company's growth strategy. Click here to read ...
Amgen posted a higher quarterly profit on Tuesday as product sales rose 11% and said late-stage studies of key obesity drug ...
Shares of the company began plunging in November, but its overall strength should set the stock up for some serious potential ...
Amgen outperformed expectations in the fourth quarter of 2024, but revealed an FDA hold on early-stage obesity asset AMG 513 ...
Shares of Amgen (Nasdaq: AMGN) started crashing in early November and didn’t improve when the company released data from a ...
All lines have been placed on mute to prevent any background noise. There will be a question-and-answer session at the ...
US biotech major Amgen presented its fourth quarter and 2024 financial results late Tuesday, along with its guidance for 2025.
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/105.JzBkOQ-g.js ...
Research from the Tufts Center for the Study of Drug Development’s PACT Consortium shows DCTs encourage higher participation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback